Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of satralizumab in anti-NMDAR or anti-LGI1 autoimmune encephalitis
CTR20223277Phase 3Active
- Sponsor
- Roche
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anti-NMDA receptor encephalitis and Anti-leucine-rich glioma inactivated 1 encephalitis comparing Enspryng with Placebo (2 arms). Primary endpoint: Proportion of participants with at least 1-point improvement from baseline in modified Rankin Scale score without rescue therapy. Started May 2023; status: active.
02
Drugs
satralizumab
03
Conditions
anti-NMDA receptor encephalitisAnti-leucine-rich glioma inactivated 1 encephalitis
Beyond the preview
Go deeper on CTR20223277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223277.